Laminar Pharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Laminar Pharma arose in 2006 as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba.
Laminar Pharma aims to develop next-generation medicines, nutraceutical and cosmetic products based on the novel Membrane-Lipid Therapy (MLT) strategy, which targets membrane lipids and/or the structures they form, rather than directly targeting specific cellular proteins. MLT-based drugs specifically interact with and modulate the activity of key signal-transduction peripheral proteins involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases.
Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs unmet, such as glioblastoma and other aggressive cancer malignancies, as well as neuro-degenerative, metabolic, cardiovascular or inflammatory diseases. These novel drugs will provide a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies.
Membrane-Lipid Therapy (MLT) is an innovative scientific platform based on an expanding area of knowledge in today’s cell biology. The most commonly used rational approach in drug design involves isolating a protein to elucidate its structure and then the design of molecules (chemicals, antibodies…) that regulate its activity. In this approach the molecules designed to interact and inhibit the activity of such membrane-associated signal transduction proliferative proteins targets are synthetic fatty acids.
This novel therapeutic approach constitutes a “disruptive innovation” that can lead to the development of transformative new medicines with an exceptional safety/efficacy combination in serious pathologies with critical medical needs unmet, such as Oncology, Neurodegenerative or metabolic diseases.
The potential translation of significant clinical benefit to patients of MLT-based products is being evaluated in different studies, such as MIN-001-1203, the first clinical trial with 2-OHOA in patients with advanced solid tumours, including malignant glioma, which has already been completed with very promising results.
Prof. Pablo V. Escribá, PhD.
President & Founder
He is Professor of Cell Biology at the University (UIB, Mallorca, Spain) and the main promoter of Laminar Pharma. He has more than twenty years of succesfull experience as a scientist and researcher. And he has held senior research stages in USA (New York, Kansas City and Charleston), Switzerland (Geneve) and Hungary (Szeged).
Adrian G. McNicholl, PhD.
Dr. McNicholl holds a PhD. in Medicine and Surgery; formerly a post-doctoral researcher at CIBERehd, he has participated in over 60 traslational research projects including the design and coordination of several clinical trials, producing over 40 indexed publications (H-index= 21). He founded in 2013 and has been the Scientific Director (until 2019) of the non-profit Spanish Platform for Collaborative Research in Gastroenterology (AEG‐REDCap) with more than 70 projects, and 1,600 researchers in 45 countries. He has coordinated several courses and books on evidence based clinical practice and traslational research, and received over 10 international awards and grants for his oral and poster presentations.
Victoria Llado, PhD.
Dr. Llado holds a degree in Biology (UIB) and in Biochemistry (UIB) and a PhD in in Molecular Biology (UIB). After postdoctoral fellow research positions at the Gastro-Intestinal Unit of MGH, Harvard Medical School (Boston, MA, USA) at the Sanford-Burnham Medical Research Institute (San Diego, CA, USA) and at the UIB (with a grant from the Asociación Española Contra el Cancer, AECC), she joined Laminar Pharma as head of the laboratory facilities and CSO of Laminar Pharma in December 2018.
Daniel Bermejo, MSc.
Clinical Trial manager
Daniel has a Degree in Biology and a Master’s in research by the University of Nottingham, UK. Over the last 12 years he has hold different professional positions in the field of Clinical Research, including Clinical Project Manager at Fina Biotech (10 years), Pharma Mar or Ely Lilly.
Catalina Ana Rossello, PhD.
Clinical R&D projects
Dr. Rossello holds a degree in Biology (UIB) and in Biochemistry (UIB) and a PhD in Molecular Biology (Autonomous University of Madrid). After a postdoctoral fellow research positions at Lund University (Sweden) and at the UIB (with a European FP7 Marie Curie grant), she joined Laminar Pharma as senior scientist (with a Felip Bauçà contract from the local Government) first and then as head of the clinical R&D scientific area. She is liaison with all other scientific areas to ensure the flow of laboratory discoveries to clinical development.
Paula Fernandez, PhD.
Director Oncology R&D
Dr. Fernandez has a degree in Biochemistry (University of Oviedo) and a PhD in Biochemistry and Molecular Biology (University of Oviedo). After a brief period at the UIB, she joined Laminar Pharma in November 2013, after obtaining a Torres Quevedo contract. Her research is developed mainly in the fields of proteomics and molecular biology. She is leading the basic and applied research aimed at further elucidating 2OHOA’s mechanism of action in oncology and at the identification and development of biomarkers to support the clinical development of 2OHOA.
Manuel Torres, PhD.
Director Neurology R&D
Dr. Torres has a degree in Pharmacy and a Master in Physiology and Neuroscience (University of Seville). He earned his PhD in biomedical sciences working in a research project in the field of Alzheimer’s pathophysiology. With 10-years expertise in this field and research stages at Sanofi-Aventis Research Centre (Paris, France) and the Catholic University of Leuven/VIB Center for Human Genetics (Leuven, Belgium), he has published multiple scientific articles in the fields of neurodegenerative disorders. He joined the scientific team of Laminar Pharma in 2013.
Emilce Cano, Bs.
Emilce holds a Degree in Pharmaceutical Chemistry, a Diploma in Quality Management and is completing a Masters in Applied Biotechnology. After leading positions in the pharmaceutical sector, she accumulated over 10 years experience in industrial property with a focus on patents. She is responsible for Intellectual Property (IP) and Project Management.
Elena Berengena, MSc.
Clinical Project Manager
Elena has Pharmacy Degree, and a master’s degree in clinical trials, with over 10 years of experience in clinical research working within Clinical Research & Development and Operations teams for the conduction of clinical trials in Oncology and inflammatory diseases.
Prof. Manuel Illescas, PhD.
He is a specialist in patent prosecution in Spain, as qualified European Patent Attorney EPA) before the European Patent Office (EPO) and via Patent Cooperation Treaty (PCT), with more than 30 years of experience, especially in the following technical sectors: pharmaceutical, chemical, environmental, biomedical and, above all, in the biotechnological sector. He has held senior executive positions in several patent managing companies, including MIAPatents, González-Bueno & Illescas, and ELZABURU, along with Venture Capital companies (Cross Road Biotech). He is also authorized to act as representative for trademarks matters before European Union Office for Intellectual Property (EUIPO), Spanish Patent Office (SPO) and World Intellectual Property Organization (WIPO).
Richard J. Taylor, PhD.
Medical & Regulatory affairs
Dr. Taylor has extensive large pharmaceutical company experience. Formerly Head of International Clinical and Regulatory Affairs with Zeneca Pharmaceuticals (now AstraZeneca), Dr. Taylor has held management positions with Fisons Pharmaceuticals (now part of Aventis) and The Wellcome Research Laboratories (now part of Glaxo SmithKline). Since 2001 he is Managing Consultant & Projects Director at The Medical & Regulatory Partnership Ltd (TMRP), a drug development consultancy specializing in global regulatory services.
Neil Dey, PhD.
Business Development & Director of Laminar Pharma Inc.
Dr. Dey has more than 20 years of cross-functional experience in licensing, international alliances, strategic marketing, technology & product development, asset acquisition, M&A, market assessment and clinical trial management. He has held senior executive positions in several biopharmaceutical companies including LMBRI LLC, Definies Ag, Impath Inc., Genmethrax Inc. or Ciba-Geigy (Novartis)
Public and private investments
He is active in both public and private investments in companies developing drugs, medical devices, diagnostics and research tools. Prior to founding Ilana Capital he was Executive Director at Goldman Sachs Special Situations Group (London, U.K.). He also worked as investment banker at J.P. Morgan and Goldman Sachs and lead several successful private transactions at Magnum Capital. Mr. Martínez holds a BS in Telecommunication Engineering from University Polytechnic of Madrid (top 1%). He is a MENSA member since 2007 and FCA approved person since 2014.
Regulatory, Business and Clinical strategies
QUALITECFARMA is a CRO that for 20 years has been dedicated to the business of managing highly qualified projects in the areas of clinical research, Monitoring, Data Management, Biostatistics, Pharmacovigilance, Scientific Drafting Regulatory Affairs, Market Access and Corporate Operations for the pharmaceutical industry.
Antoine Perier, DEA.
Clinical Trial Methodology